RE:RE:RE:RE:Anyone think it was oddWillingly not proceeding with Nash is NOT an option,...They did an Offering based mostly on the need to fund a Phase 3 Nash trial,,,
scarlet1967 wrote: They did start with an introduction of legacy drugs and NASH but as many suggested they are currently in the process of finalizing the NASH protocol to get both agencies onboard so once that is done they can talk publicly about it.
They did although briefly start with legacy drugs and NASH( got letter to proceed for phase 3) but the focus was mostly on cancer trial which is due sooner than NASH.
They are too far gone in the process for NASH which is a big financial opportunity to give it up. The early cancer results if encouraging would push the SP much higher, make them more confident to push forward with more costly/lengthy NASH trial and if not encouraging or outright flop that would make NASH even more important as that would be the only R&D program left to go forward with.
Also the cancer trial can fail right at the end maybe less likely but still..,
Look at intercept still trying to push a head with the phase 3 NASH yet their drug is currently under investigation by FDA for lethal adverse effects.
NASH is too large of financial opportunity to be given up.
Wino115 wrote: I noticed that at the original "fireside chat", but what I figure is that they only paid for a quick 30 minute "pitch" and follow up and made the correct decision to provide the full picture up front (which included the discussion of NASH, Phase 3 and their excitement to go for two large markets) but then to pivot to the one trial coming up first and that will provide the next 12 months of newsflow via AACR, dosage escalation, etc.. I'm pretty sure they aren't turning their attention away from NASH either given Phase 3 is still a huge deal. Just that cancer is fast approaching. Probably they also saw that for the new investors, that's what they may have focused on initially with NASH being secondary given the timeline.
realitycheck4u wrote: They did it right. Telling a story requires Clarity. Doesn't matter there are other stories. Tell this one. Sell it to your audience. Period. Do not stray. Do not crowd your message with other good messages. Just very briefly. Done. Now if they started taking about Nash, people would get board and think they're in too many things. Focus. Focus. Focus. This was how it should have been done.
SPCEO1 wrote: that the Water Tower Research paid for piece focused on cancer and basically overlooked NASH? Is there a reason (besides the FDA meeting and working to get the EMA on board) we don't know about for pushing the start of the NASH trial out to the third quarter? Is the reason they sold equity and warrants at a zero value for NASH because the company does not believe in their NASH plans and might deep six it if the early cancer data looks really promising? Just trying to connect some dots but may be trying to hard to do so.